127 Patents, Ponezumab Alzheimer's drug in Phase 2 with PFE (based on ANTISENILIN PLATFORM - ILNS), OX1 FRIDREICH ATAXIA DRUG - $120 million deal with VPHM, Expecting excited Tauc3 results, Conjumab Antisenilin RecallVax Oligotope
when is this phase three study estimated to be done.
Sentiment: Strong Buy
More infos on IHUB BOARD - ILNS, IBOX, Posts #9599, #9600 etc.
More infos on IHUB